Arnesen A (Institute of Community Medicine, University of Tromsphi, MH-building, N-9037 Tromsphi, Norway), Refsum H, Bphinaa K H, Ueland P M, Fphirde OH and Nordrehaug J E. Serum total homocysteine and coronary heart disease.
International Journal of Epidemiology 1995 ; 24 : 704-709.
Several studies have observed high plasma levels of homocysteine among patients with coronary heart disease (CHD).
The only prospective study was based on US physicians, and concluded that homocysteine was associated with subsequent myocardial infarction (MI).
However, the association was limited to those above a threshold level of homocysteine.
We conducted a nested case-control study among the 21 826 subjects, aged 12-61 years, who were surveyed in the municipality of Tromsphi, Norway.
Among those free from Ml at the screening, 123 later developed CHD.
Four controls were selected for each case.
Level of homocysteine was higher in cases than in controls (12.7 ± 4.7 versus 11.3 ± 3.7 mumol/l (mean ± SD) ; P=0.002).
The relative risk for a 4 mumol/l increase in serum homocysteine was 1.41 (95% confidence interval (Cl) : 1.16-1.71).
Adjusting for possible confounders reduced the relative risk to 1.32 (95% Cl : 1.05-1.65).
There was no threshold level above which serum homocysteine is associated with CHD events.
In the general population serum total homocysteine is an independent risk factor for CHD with no threshold level.
Mots-clés Pascal : Cardiopathie coronaire, Epidémiologie, Homme, Homocystéine, Taux, Norvège, Europe, Aminoacide soufré, Thiol, Appareil circulatoire pathologie
Mots-clés Pascal anglais : Coronary heart disease, Epidemiology, Human, Rate, Norway, Europe, Sulfur containing aminoacid, Thiol, Cardiovascular disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0472609
Code Inist : 002B12A03. Création : 01/03/1996.